| Mr Khursheed A Siddiqui, MD | |
|
300 West Broadway, Danville, KY 40422-1408 | |
| (859) 236-0606 | |
| (859) 236-0066 |
| Full Name | Mr Khursheed A Siddiqui |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 36 Years |
| Location | 300 West Broadway, Danville, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881634368 | NPI | - | NPPES |
| 64287410 | Medicaid | KY |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ephraim Mcdowell Regional Medical Center | Danville, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advanced Family Medical Clinic Mount Vernon | 2062780810 | 6 |
| Advanced Family Medical Clinic Liberty | 3173891926 | 6 |
| Ephraim Mcdowell Health Resource Inc | 7517876956 | 115 |
News Archive
An international consortium of scientists, including a team from The University of Queensland's Institute for Molecular Bioscience (IMB), is a step closer to the next generation of treatments to combat disease, after publishing a comprehensive analysis of the human and mouse transcriptomes.
The results of a new study suggest that nocturnal enuresis, or bedwetting, may be an additional symptom that doctors can look for when assessing post-menopausal women for obstructive sleep apnea. That condition left untreated can lead to serious medical problems, such as cardiovascular disease, as organs are undersupplied with oxygen.
Inequitable access to health care is a pressing global health concern, and care of our teeth is no exception. In fact, the World Health Organization established the Global Goals for Oral Health 2020 in its efforts to help counter socioeconomic-related imbalances.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).
What didn't make the cut? ... A "grand bargain": For three years, Obama pursued a big fiscal deal that would have traded higher taxes (a Democratic goal) for cuts in long-term spending on Medicare, Medicaid and Social Security (a Republican goal).
› Verified 5 days ago
| Entity Name | University Of Kentucky |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770771974 PECOS PAC ID: 3072425289 Enrollment ID: O20031105000072 |
News Archive
An international consortium of scientists, including a team from The University of Queensland's Institute for Molecular Bioscience (IMB), is a step closer to the next generation of treatments to combat disease, after publishing a comprehensive analysis of the human and mouse transcriptomes.
The results of a new study suggest that nocturnal enuresis, or bedwetting, may be an additional symptom that doctors can look for when assessing post-menopausal women for obstructive sleep apnea. That condition left untreated can lead to serious medical problems, such as cardiovascular disease, as organs are undersupplied with oxygen.
Inequitable access to health care is a pressing global health concern, and care of our teeth is no exception. In fact, the World Health Organization established the Global Goals for Oral Health 2020 in its efforts to help counter socioeconomic-related imbalances.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).
What didn't make the cut? ... A "grand bargain": For three years, Obama pursued a big fiscal deal that would have traded higher taxes (a Democratic goal) for cuts in long-term spending on Medicare, Medicaid and Social Security (a Republican goal).
› Verified 5 days ago
| Entity Name | Kentucky Medical Services Foundation, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326091448 PECOS PAC ID: 5698689909 Enrollment ID: O20031119000300 |
News Archive
An international consortium of scientists, including a team from The University of Queensland's Institute for Molecular Bioscience (IMB), is a step closer to the next generation of treatments to combat disease, after publishing a comprehensive analysis of the human and mouse transcriptomes.
The results of a new study suggest that nocturnal enuresis, or bedwetting, may be an additional symptom that doctors can look for when assessing post-menopausal women for obstructive sleep apnea. That condition left untreated can lead to serious medical problems, such as cardiovascular disease, as organs are undersupplied with oxygen.
Inequitable access to health care is a pressing global health concern, and care of our teeth is no exception. In fact, the World Health Organization established the Global Goals for Oral Health 2020 in its efforts to help counter socioeconomic-related imbalances.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).
What didn't make the cut? ... A "grand bargain": For three years, Obama pursued a big fiscal deal that would have traded higher taxes (a Democratic goal) for cuts in long-term spending on Medicare, Medicaid and Social Security (a Republican goal).
› Verified 5 days ago
| Entity Name | Danville Anesthesia Associates, Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821038696 PECOS PAC ID: 9032016910 Enrollment ID: O20031218000008 |
News Archive
An international consortium of scientists, including a team from The University of Queensland's Institute for Molecular Bioscience (IMB), is a step closer to the next generation of treatments to combat disease, after publishing a comprehensive analysis of the human and mouse transcriptomes.
The results of a new study suggest that nocturnal enuresis, or bedwetting, may be an additional symptom that doctors can look for when assessing post-menopausal women for obstructive sleep apnea. That condition left untreated can lead to serious medical problems, such as cardiovascular disease, as organs are undersupplied with oxygen.
Inequitable access to health care is a pressing global health concern, and care of our teeth is no exception. In fact, the World Health Organization established the Global Goals for Oral Health 2020 in its efforts to help counter socioeconomic-related imbalances.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).
What didn't make the cut? ... A "grand bargain": For three years, Obama pursued a big fiscal deal that would have traded higher taxes (a Democratic goal) for cuts in long-term spending on Medicare, Medicaid and Social Security (a Republican goal).
› Verified 5 days ago
| Entity Name | Ephraim Mcdowell Health Resource Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487708533 PECOS PAC ID: 7517876956 Enrollment ID: O20031218000776 |
News Archive
An international consortium of scientists, including a team from The University of Queensland's Institute for Molecular Bioscience (IMB), is a step closer to the next generation of treatments to combat disease, after publishing a comprehensive analysis of the human and mouse transcriptomes.
The results of a new study suggest that nocturnal enuresis, or bedwetting, may be an additional symptom that doctors can look for when assessing post-menopausal women for obstructive sleep apnea. That condition left untreated can lead to serious medical problems, such as cardiovascular disease, as organs are undersupplied with oxygen.
Inequitable access to health care is a pressing global health concern, and care of our teeth is no exception. In fact, the World Health Organization established the Global Goals for Oral Health 2020 in its efforts to help counter socioeconomic-related imbalances.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).
What didn't make the cut? ... A "grand bargain": For three years, Obama pursued a big fiscal deal that would have traded higher taxes (a Democratic goal) for cuts in long-term spending on Medicare, Medicaid and Social Security (a Republican goal).
› Verified 5 days ago
| Entity Name | Central Kentucky Interventional Pain Center, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407855935 PECOS PAC ID: 0143292748 Enrollment ID: O20040812000474 |
News Archive
An international consortium of scientists, including a team from The University of Queensland's Institute for Molecular Bioscience (IMB), is a step closer to the next generation of treatments to combat disease, after publishing a comprehensive analysis of the human and mouse transcriptomes.
The results of a new study suggest that nocturnal enuresis, or bedwetting, may be an additional symptom that doctors can look for when assessing post-menopausal women for obstructive sleep apnea. That condition left untreated can lead to serious medical problems, such as cardiovascular disease, as organs are undersupplied with oxygen.
Inequitable access to health care is a pressing global health concern, and care of our teeth is no exception. In fact, the World Health Organization established the Global Goals for Oral Health 2020 in its efforts to help counter socioeconomic-related imbalances.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).
What didn't make the cut? ... A "grand bargain": For three years, Obama pursued a big fiscal deal that would have traded higher taxes (a Democratic goal) for cuts in long-term spending on Medicare, Medicaid and Social Security (a Republican goal).
› Verified 5 days ago
| Entity Name | United Clinics Of Kentucky Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427161769 PECOS PAC ID: 2668457094 Enrollment ID: O20050225000679 |
News Archive
An international consortium of scientists, including a team from The University of Queensland's Institute for Molecular Bioscience (IMB), is a step closer to the next generation of treatments to combat disease, after publishing a comprehensive analysis of the human and mouse transcriptomes.
The results of a new study suggest that nocturnal enuresis, or bedwetting, may be an additional symptom that doctors can look for when assessing post-menopausal women for obstructive sleep apnea. That condition left untreated can lead to serious medical problems, such as cardiovascular disease, as organs are undersupplied with oxygen.
Inequitable access to health care is a pressing global health concern, and care of our teeth is no exception. In fact, the World Health Organization established the Global Goals for Oral Health 2020 in its efforts to help counter socioeconomic-related imbalances.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).
What didn't make the cut? ... A "grand bargain": For three years, Obama pursued a big fiscal deal that would have traded higher taxes (a Democratic goal) for cuts in long-term spending on Medicare, Medicaid and Social Security (a Republican goal).
› Verified 5 days ago
| Entity Name | Advanced Family Medical Clinic Mount Vernon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578090403 PECOS PAC ID: 2062780810 Enrollment ID: O20171026003512 |
News Archive
An international consortium of scientists, including a team from The University of Queensland's Institute for Molecular Bioscience (IMB), is a step closer to the next generation of treatments to combat disease, after publishing a comprehensive analysis of the human and mouse transcriptomes.
The results of a new study suggest that nocturnal enuresis, or bedwetting, may be an additional symptom that doctors can look for when assessing post-menopausal women for obstructive sleep apnea. That condition left untreated can lead to serious medical problems, such as cardiovascular disease, as organs are undersupplied with oxygen.
Inequitable access to health care is a pressing global health concern, and care of our teeth is no exception. In fact, the World Health Organization established the Global Goals for Oral Health 2020 in its efforts to help counter socioeconomic-related imbalances.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).
What didn't make the cut? ... A "grand bargain": For three years, Obama pursued a big fiscal deal that would have traded higher taxes (a Democratic goal) for cuts in long-term spending on Medicare, Medicaid and Social Security (a Republican goal).
› Verified 5 days ago
| Entity Name | Advanced Family Medical Clinic Liberty |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023545241 PECOS PAC ID: 3173891926 Enrollment ID: O20171026003580 |
News Archive
An international consortium of scientists, including a team from The University of Queensland's Institute for Molecular Bioscience (IMB), is a step closer to the next generation of treatments to combat disease, after publishing a comprehensive analysis of the human and mouse transcriptomes.
The results of a new study suggest that nocturnal enuresis, or bedwetting, may be an additional symptom that doctors can look for when assessing post-menopausal women for obstructive sleep apnea. That condition left untreated can lead to serious medical problems, such as cardiovascular disease, as organs are undersupplied with oxygen.
Inequitable access to health care is a pressing global health concern, and care of our teeth is no exception. In fact, the World Health Organization established the Global Goals for Oral Health 2020 in its efforts to help counter socioeconomic-related imbalances.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).
What didn't make the cut? ... A "grand bargain": For three years, Obama pursued a big fiscal deal that would have traded higher taxes (a Democratic goal) for cuts in long-term spending on Medicare, Medicaid and Social Security (a Republican goal).
› Verified 5 days ago
| Entity Name | Center For Recovery And Wellness |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427404037 PECOS PAC ID: 4981961893 Enrollment ID: O20171201000853 |
News Archive
An international consortium of scientists, including a team from The University of Queensland's Institute for Molecular Bioscience (IMB), is a step closer to the next generation of treatments to combat disease, after publishing a comprehensive analysis of the human and mouse transcriptomes.
The results of a new study suggest that nocturnal enuresis, or bedwetting, may be an additional symptom that doctors can look for when assessing post-menopausal women for obstructive sleep apnea. That condition left untreated can lead to serious medical problems, such as cardiovascular disease, as organs are undersupplied with oxygen.
Inequitable access to health care is a pressing global health concern, and care of our teeth is no exception. In fact, the World Health Organization established the Global Goals for Oral Health 2020 in its efforts to help counter socioeconomic-related imbalances.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).
What didn't make the cut? ... A "grand bargain": For three years, Obama pursued a big fiscal deal that would have traded higher taxes (a Democratic goal) for cuts in long-term spending on Medicare, Medicaid and Social Security (a Republican goal).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Khursheed A Siddiqui, MD 300 West Broadway, Danville, KY 40422-1408 Ph: (859) 236-0606 | Mr Khursheed A Siddiqui, MD 300 West Broadway, Danville, KY 40422-1408 Ph: (859) 236-0606 |
News Archive
An international consortium of scientists, including a team from The University of Queensland's Institute for Molecular Bioscience (IMB), is a step closer to the next generation of treatments to combat disease, after publishing a comprehensive analysis of the human and mouse transcriptomes.
The results of a new study suggest that nocturnal enuresis, or bedwetting, may be an additional symptom that doctors can look for when assessing post-menopausal women for obstructive sleep apnea. That condition left untreated can lead to serious medical problems, such as cardiovascular disease, as organs are undersupplied with oxygen.
Inequitable access to health care is a pressing global health concern, and care of our teeth is no exception. In fact, the World Health Organization established the Global Goals for Oral Health 2020 in its efforts to help counter socioeconomic-related imbalances.
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).
What didn't make the cut? ... A "grand bargain": For three years, Obama pursued a big fiscal deal that would have traded higher taxes (a Democratic goal) for cuts in long-term spending on Medicare, Medicaid and Social Security (a Republican goal).
› Verified 5 days ago